Explained | Molnupiravir, Merck’s new drug to treat COVID-19
3 years, 2 months ago

Explained | Molnupiravir, Merck’s new drug to treat COVID-19

The Hindu  

Why is there much excitement about molnupiravir, the investigational new drug for COVID-19? Pharmaceutical major Merck and Ridgeback Biotherapeutics announced via a press release on October 1 the early results from Phase-3 trials that its anti-viral drug molnupiravir halved the chances of hospitalisation in COVID-19 patients with mild or moderate disease. Several noted clinicians have said that these are promising results, and what is particularly encouraging is that molnupiravir is a pill, unlike other drugs — with similar efficacy — used in COVID-19 treatment, which needs to be administered intravenously. The drug has so far been tested only in patients with mild-to-moderate COVID-19, had started treatment within five days of testing positive and had at least one risk factor that increased their risk for severe disease. Another positive factor is that recruitment for the phase-3 trial, that originally envisaged recruiting 1,500 patients for testing the drug’s potency, was halted early by an independent data monitoring committee because the data appeared so encouraging that it would be unethical to delay making the drug more widely available.

Treatment Data Patients Covid Drug Treat Thor Merck Pill Placebo Molnupiravir  phase3  mercks  explained  merck  data  covid19  molnupiravir  patients  placebo  treatment  pill  treat  drug

History of this topic

Molnupiravir Leads To Quicker Recovery In Vaccinated Adults Infected With Covid Does Not Reduce Hospital Admission Or Death Study In Lancet
2 years ago

Molnupiravir Leads To Quicker Recovery In Vaccinated Adults Infected With Covid Does Not Reduce Hospital Admission Or Death Study In Lancet

ABP News  

Molnupiravir leads to quicker recovery in vaccinated adults infected with Covid-19, compared to individuals who did not consume the pills, according to a new study published in The Lancet journal. The study also found that molnupiravir does not reduce hospitalisation or death in vaccinated adults infected with Covid-19, who are at a higher risk of mortality. Quicker recovery in patients …

VINCOV-19, country’s first anti-dote for COVID, ready for phase 3 trials, market authorisation
2 years, 2 months ago

VINCOV-19, country’s first anti-dote for COVID, ready for phase 3 trials, market authorisation

The Hindu  

The University of Hyderabad and CSIR-Centre for Cellular & Molecular Biology in collaboration with VINS Bioproducts Limited, an immunological company based here, have announced the successful completion of phase 2 clinical trials of ‘VINCOV-19’, touted to be the country’s first antidote and a cure against SARS-CoV-2 virus. VINCOV-19 is now ready for market authorisation and for simultaneous phase 3 clinical …

What is Paxlovid and Who Can Take Pfizer’s Covid-19 Wonder Drug ‘Strongly Recommended’ by WHO?
2 years, 8 months ago

What is Paxlovid and Who Can Take Pfizer’s Covid-19 Wonder Drug ‘Strongly Recommended’ by WHO?

News 18  

Paxlovid, Pfizer’s Covid-19 antiviral pill, has been “strongly recommended” by the World Health Organization for patients with milder forms of the disease who are still at high risk of hospitalisation. WHO experts have said that Pfizer’s oral treatment prevents hospitalisation more than the “available alternatives, has fewer concerns with respect to harms than Molnupiravir, and is easier to administer than …

Health Matters: Dear Drug Regulator, Silence is Not Always Golden, Esp on WHO Pausing Covaxin Supply
2 years, 8 months ago

Health Matters: Dear Drug Regulator, Silence is Not Always Golden, Esp on WHO Pausing Covaxin Supply

News 18  

On April 2, the World Health Organization suspended the supply of Bharat Biotech’s Covaxin through the UN agencies after finding issues with the “good manufacturing practices”. For the past 15 days, not only health journalists, but even commoners who got Covaxin jabs are hoping to hear from the country’s drug regulatory agency – Central Drugs Standard Control Organization. Eventually, the …

COVID-19 pills could be a game-changer, but doctors trying to use them face hurdles
2 years, 9 months ago

COVID-19 pills could be a game-changer, but doctors trying to use them face hurdles

LA Times  

Jeff Carlson, a Type 1 diabetic with heart stents, came down with COVID-19 in January, but recovered quickly after being treated with Merck’s molnupiravir. With vaccines and treatments available, “we can make this much more manageable in the future, if people are willing to take care of themselves,” said Dr. Bryan Jarabek, who helps lead COVID-19 treatment and vaccination efforts …

'Prepare for new COVID-19 variants': Joe Biden tells pandemic-weary Americans
2 years, 9 months ago

'Prepare for new COVID-19 variants': Joe Biden tells pandemic-weary Americans

Firstpost  

In his first State of the Union Address on Tuesday, Biden said thanks to the progress the country has made last year, COVID-19 need no longer controls the lives of the Americans. President Joe Biden has urged Americans to prepare themselves for new coronavirus variants as he launched a new initiative aimed at helping COVID-19-infected people to get tested at …

Covid-19 pill competing with Pfizer’s looks for quick approval in Japan
2 years, 10 months ago

Covid-19 pill competing with Pfizer’s looks for quick approval in Japan

Live Mint  

TOKYO : Drugmaker Shionogi & Co. said it plans to seek approval this month to sell its Covid-19 treatment pill in Japan after the company found that in human trials the pill had strong virus-fighting ability compared with Pfizer Inc.’s Paxlovid. Pfizer said its final-stage trial, which included more than 2,000 patients, showed Paxlovid cut the risk of hospitalization or …

Generic Drugmakers to Make Cheap Versions of Merck's Covid-19 Pill Molnupiravir for Poorer Nations
2 years, 11 months ago

Generic Drugmakers to Make Cheap Versions of Merck's Covid-19 Pill Molnupiravir for Poorer Nations

News 18  

A UN-backed agency has struck a deal for nearly 30 generic drugmakers to make low-cost versions of Merck & Co’s Covid-19 pill molnupiravir for poorer nations, widening access to a drug seen as a weapon in fighting the pandemic. A molnupiravir course of 40 pills for five days is expected to cost about $20 in poorer nations, an MPP official …

Cheap version of Merck Covid pill to be made for poorer nations
2 years, 11 months ago

Cheap version of Merck Covid pill to be made for poorer nations

India Today  

A UN-backed agency has struck a deal for nearly 30 generic drugmakers to make low-cost versions of Merck & Co's Covid-19 pill molnupiravir for poorer nations, widening access to a drug seen as a weapon in fighting the pandemic. The agreement, negotiated by the UN-backed Medicines Patent Pool with Merck, allows 27 generic drugmakers from India, China and other countries …

Molnupiravir kept out of revised clinical guidelines for management of adult COVID-19 patients
2 years, 11 months ago

Molnupiravir kept out of revised clinical guidelines for management of adult COVID-19 patients

The Hindu  

The Central government hasn’t included antiviral drug Molnupiravir in its revised clinical guidance for management of adult COVID-19 patients, and specified that Remdesivir and Tocilizumab should be prescribed under certain conditions only. The guidelines were revised by the All India Institute of Medical Science and Indian Council of Medical Research -COVID-19 National Task Force/ Joint Monitoring Group, under the Health …

WHO adds new drugs to COVID treatments amid Omicron surge
2 years, 11 months ago

WHO adds new drugs to COVID treatments amid Omicron surge

Al Jazeera  

Latest recommendations prompt new calls for patent waivers to allow more people access to treatments. The drug baricitinib, which is also used to treat rheumatoid arthritis, is “strongly recommended” for patients with severe or critical COVID-19, in combination with corticosteroids, the UN agency’s panel of international experts said in the guidelines which were published by the British Medical Journal on …

No molnupiravir: ICMR team
2 years, 11 months ago

No molnupiravir: ICMR team

The Hindu  

The ICMR’s National Task Force for COVID-19 has decided against including antiviral drug molnupiravir in the Clinical Management Protocol for COVID-19 as of now, official sources said on Tuesday. The experts of the task force cited safety concerns, and argued that Molnupiravir was not of much benefit in COVID treatment to arrive at the decision in a meeting held on …

Lupin launches antiviral medication Molnulup for COVID-19 treatment in India
2 years, 11 months ago

Lupin launches antiviral medication Molnulup for COVID-19 treatment in India

Firstpost  

Molnupiravir has been given emergency use authorisation by the DCGI for treatment of adult COVID-19 patients who have a high risk of progression of the disease, including hospitalisation. New Delhi: Drugmaker Lupin on Friday said it has launched antiviral medication Molnupiravir under the brand name Molnulup in the country for the treatment of COVID-19. Molnupiravir has been given emergency use …

Covid antiviral drug Molnupiravir has major safety concerns: ICMR chief
2 years, 11 months ago

Covid antiviral drug Molnupiravir has major safety concerns: ICMR chief

The Hindu  

ICMR Chief Dr. Balram Bhargava said on January 5 that Covid antiviral drug Molnupiravir has major safety concerns and has not been included in the national protocol for treatment of coronavirus. “Molnupiravir will now be manufactured in the country by 13 companies for restricted use under emergency situations for treatment of adult patients with COVID-19 and who have high risk …

Molnupiravir, oral anti-Covid medicine, set for launch in India; to cost Rs 649 per strip
2 years, 11 months ago

Molnupiravir, oral anti-Covid medicine, set for launch in India; to cost Rs 649 per strip

India TV News  

Molnupiravir, the world’s first and only oral antiviral to be approved by the US FDA, UK MHRA and Indian CDSCO for treatment of COVID-19, is set for a launch. Last week, the Drugs Controller General of India, based on the review of clinical data of molnupiravir, approved molnupiravir for treatment of adult patients with Covid-19, with SpO2 > 93% and …

EXPLAINED: As Covid Antiviral Molnupiravir Launches In India, Here's All You Need To Know About The Pill
2 years, 11 months ago

EXPLAINED: As Covid Antiviral Molnupiravir Launches In India, Here's All You Need To Know About The Pill

News 18  

Days after it received an emergency use nod from the Indian drugs regulator, the antiviral molnupiravir has already hit the markets with more than a dozen Indian companies working on rolling out the pill by taking advantage of the patent waiver offered by its American makers for production in low- and middle-income countries. Molnupiravir has received an emergency nod in …

Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week
2 years, 11 months ago

Mankind Pharma to Launch Cheapest Covid Antiviral Drug Molnupiravir at Rs 35 Per Capsule by Next Week

News 18  

Mankind Pharma’s chairman has said the company’s will launch the cheapest Molnupiravir, the Covid-19 antiviral drug, at Rs 35 per capsule, the Economic Times said in a report. Molnupiravir, developed by MSD and Ridgeback Biotherapeutics, has been approved by the UK Medicines and Healthcare products Regulatory Agency and the US Food and Drug Administration for the treatment of mild-to-moderate Covid-19 …

New Covid-19 pills carry risks: What patients should know
2 years, 11 months ago

New Covid-19 pills carry risks: What patients should know

Live Mint  

The first Covid-19 antiviral pills that can be taken at home are a new treatment option for infected people, but they carry safety warnings and limitations that could complicate treatment decisions for patients, doctors and pharmacists. In December, the Food and Drug Administration authorized the use of new pills from Merck & Co., with its partner Ridgeback Biotherapeutics, and Pfizer …

Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know
2 years, 11 months ago

Optimus Pharma to launch anti-COVID pill Molnupiravir next week; all you need to know

Firstpost  

Molnupiravir, developed by US-based biotechnology company Ridgeback Biotherapeutics in collaboration with US pharma giant Merck, was approved for emergency use in India on Tuesday The Drug Controller General of India had earlier this week approved Molnupiravir for restricted use in an emergency situation in India. Brinton Pharmaceuticals on Thursday said it will launch its generic version of anti-COVID-19 pill Molnupiravir …

Approved by India, Full Treatment of Anti-Viral Drug Molnupiravir May Cost Up to Rs 3,000: Report
2 years, 11 months ago

Approved by India, Full Treatment of Anti-Viral Drug Molnupiravir May Cost Up to Rs 3,000: Report

News 18  

Anti-viral drug Molnupiravir, which has got the green flag from the Drug Controller General of India for emergency use approval to treat Covid-19, is expected to cost between ₹2,000 and ₹3,000 for full treatment. Earlier, Merck had said it “plans to implement a tiered pricing approach based on World Bank country income criteria to reflect countries’ relative ability to finance …

Molnupiravir Anti-Viral Pill to be Tested on 13,000 More Patients, Makers to Submit Report in 3 Months
2 years, 11 months ago

Molnupiravir Anti-Viral Pill to be Tested on 13,000 More Patients, Makers to Submit Report in 3 Months

News 18  

The first oral anti-viral Covid pill, Molnupiravir, which was approved for the emergency use in India on Tuesday, will be tested on additional 13,000 patients to assess the safety of the drug, and companies will have to submit a report on the updated details of the clinical trial to the government, News18 has learnt. According to the document, accessed by …

Paxlovid and Molnupiravir | A new front in the battle against the pandemic
2 years, 11 months ago

Paxlovid and Molnupiravir | A new front in the battle against the pandemic

The Hindu  

The U.S. Food and Drugs Administration has given an Emergency Use Authorisation to two drugs: Paxlovid, a treatment regimen developed by Pfizer Inc for treating mild-to-moderate Covid-19 in adults and children 12 years and older, who are likely to be at greater risk for severe infection, and Molnupiravir, developed by Merck and Ridgeback Biotherapeutics to treat mild-to-moderate COVID-19 in adults …

A shot in the arm: The Hindu Editorial on new modes of COVID-19 treatment
3 years ago

A shot in the arm: The Hindu Editorial on new modes of COVID-19 treatment

The Hindu  

If full vaccination using any COVID-19 vaccine greatly reduces a person’s risk of progressing to severe disease and death, then the move by the U.S. FDA to grant emergency-use authorisation to two oral antiviral drugs for certain categories of people who are likely to become severely ill provides a much-needed fillip to fight the disease. Unlike in the case of …

Live updates: Japan approves use of Merck's COVID-19 pill
3 years ago

Live updates: Japan approves use of Merck's COVID-19 pill

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy TOKYO — Japan has approved …

Chandrakant Lahariya | FDA approval of Covid pill a sign of hope for the world
3 years ago

Chandrakant Lahariya | FDA approval of Covid pill a sign of hope for the world

Deccan Chronicle  

On December 22, the US Food and Drugs Administration approved an oral Covid-19 drug Paxlovid. This understanding has practical relevance in Covid-19 clinical management, that the antiviral drugs work better in the first phase and the immunomodulators, immunosuppressive/anti-inflammatory drugs in the later phase. Nearly all currently available Covid-19 drugs need to be given either intravenously or through injections, in hospital …

US adds Merck pill as 2nd easy-to-use drug against COVID-19
3 years ago

US adds Merck pill as 2nd easy-to-use drug against COVID-19

Associated Press  

WASHINGTON — U.S. health regulators on Thursday authorized the second pill against COVID-19, providing another easy-to-use medication to battle the rising tide of omicron infections. The FDA authorized Merck’s drug for adults with a positive COVID-19 test, early symptoms and who face the highest risks of hospitalization, including older people and those with conditions like obesity and heart disease. Additionally, …

US adds Merck pill as 2nd easy-to-use drug against Covid-19
3 years ago

US adds Merck pill as 2nd easy-to-use drug against Covid-19

India Today  

US health regulators on Thursday authorised the second pill against Covid-19, providing another easy-to-use medication to battle the rising tide of omicron infections. The Food and Drug Administration authorized Merck's drug for adults with early symptoms of Covid-19 who face the highest risks of hospitalisation, including older people and those with conditions like obesity and heart disease. Additionally, Pfizer's drug …

U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19
3 years ago

U.S. adds Merck pill as 2nd easy-to-use drug against COVID-19

LA Times  

U.S. regulators have authorized a second pill against COVID-19: molnupiravir, an antiviral drug from Merck that may help blunt the wave of coronavirus infections. The Food and Drug Administration authorized Merck’s drug for adults with early symptoms of COVID-19 who face the highest risks of hospitalization, including older people and those with conditions such as obesity and heart disease. Additionally, …

Merck’s at-home antiviral COVID-19 pill approved by US regulator
3 years ago

Merck’s at-home antiviral COVID-19 pill approved by US regulator

Al Jazeera  

United States health regulators have authorised a second antiviral pill against COVID-19, providing another easy-to-use medication to battle the rising tide of Omicron infections. Additionally, Pfizer’s drug was roughly three times more effective in testing than Merck’s, reducing hospitalisation and death by nearly 90 percent among high-risk patients. Merck’s drug is not authorised for use in patients younger than 18 …

France scraps order for Merck's Covid antiviral drug after disappointing trial results
3 years ago

France scraps order for Merck's Covid antiviral drug after disappointing trial results

India Today  

France has cancelled its order for Merck & Co's Covid-19 antiviral drug following disappointing trial data and hopes instead to receive Pfizer's competing drug before the end of January, the health minister said on Wednesday. France is the first country to publicly say it has cancelled an order for the Merck treatment after the company released data in late November …

As Omicron peaks, here's the status of 3 Covid-19 drugs Molnupiravir, Paxlovid and Ronapreve
3 years ago

As Omicron peaks, here's the status of 3 Covid-19 drugs Molnupiravir, Paxlovid and Ronapreve

India Today  

On Friday, Delhi Health Minister Satyendar Jain said 10 new cases of the new coronavirus variant, Omicron, have been detected in the national capital, taking the tally to 20. Pfizer said earlier this week that Paxlovid appears effective against the new Omicron variant. Availability in India and world The European Union drug regulator issued advice, earlier this week, on the …

Merck's Covid-19 pill Molnupiravir found to reduce hospitalisation, death risks
3 years ago

Merck's Covid-19 pill Molnupiravir found to reduce hospitalisation, death risks

India Today  

As Covid-19 cases peak across the world including the US and the UK, Molnupiravir, an oral drug developed by Merck, could act as a counter. In the phase-III clinical trials, the drug was found to reduce the risk of hospitalisation and death in at-risk, unvaccinated adults, Molnupiravir is an oral, small-molecule antiviral prodrug that is active against severe acute respiratory …

Pfizer confirms COVID pill’s results, potency versus omicron
3 years ago

Pfizer confirms COVID pill’s results, potency versus omicron

Associated Press  

WASHINGTON — Pfizer said Tuesday that its experimental pill to treat COVID-19 appears effective against the omicron variant. The company also said full results of its 2,250-person study confirmed the pill’s promising early results against the virus: The drug reduced combined hospitalizations and deaths by about 89% among high-risk adults when taken shortly after initial COVID-19 symptoms. The Food and …

Pfizer confirms COVID pill’s results, potency versus Omicron
3 years ago

Pfizer confirms COVID pill’s results, potency versus Omicron

The Hindu  

Pfizer said on Tuesday that its experimental COVID-19 pill appears effective against the omicron variant. The company also said full results of its 2,250-person study confirmed the pill’s promising early results against the virus: The drug reduced combined hospitalizations and deaths by about 89% among high-risk adults when taken shortly after initial COVID-19 symptoms. The Food and Drug Administration is …

Pfizer says its COVID-19 treatment pill works against the Omicron variant
3 years ago

Pfizer says its COVID-19 treatment pill works against the Omicron variant

LA Times  

Pfizer says its COVID-19 treatment pill appears to be effective against the Omicron variant. Pfizer said Tuesday that its experimental COVID-19 pill appears to be effective against the Omicron variant of the coronavirus. The company also said full results of its 2,250-person study confirmed the pill’s promising early results against the virus: The drug reduced combined hospitalizations and deaths by …

UK planning to rollout Merck's anti-Covid pill as soon as Christmas: Report
3 years ago

UK planning to rollout Merck's anti-Covid pill as soon as Christmas: Report

Hindustan Times  

The government in the United Kingdom is planning to roll out the antiviral pill against Coronavirus disease as part of an offered treatment against the viral disease, according to a report by Sunday Telegraph. The pill -- Molnupiravir -- has been developed by American pharmaceutical company Merck and has been touted as "game-changing" as it can be taken from the …

Merck’s covid-19 pill backed by FDA advisers
3 years ago

Merck’s covid-19 pill backed by FDA advisers

Live Mint  

An outside panel of scientific advisers to the Food and Drug Administration narrowly recommended the agency authorize the experimental Covid-19 oral antiviral from Merck & Co. and partner Ridgeback Biotherapeutics LP. Several panel members who voted in favor of authorization said use of molnupiravir should be limited to unvaccinated people at high risk of Covid-19 complications, and that while more …

US panel backs first-of-a-kind COVID-19 pill from Merck
3 years ago

US panel backs first-of-a-kind COVID-19 pill from Merck

Associated Press  

WASHINGTON — A panel of U.S. health advisers on Tuesday narrowly backed a closely watched COVID-19 pill from Merck, setting the stage for a likely authorization of the first drug that Americans could take at home to treat the coronavirus. The Food and Drug Administration panel voted 13-10 that the antiviral drug’s benefits outweigh its risks, including potential birth defects …

US panel backs Merck's first-of-a-kind Covid-19 pill
3 years ago

US panel backs Merck's first-of-a-kind Covid-19 pill

Hindustan Times  

A panel of US health advisers on Tuesday narrowly backed a closely watched Covid-19 pill from Merck, setting the stage for a likely authorization of the first drug that Americans could take at home to treat the coronavirus. A Food and Drug Administration panel voted 13-10 that the drug’s benefits outweigh its risks, including potential birth defects if used during …

US health panel endorses Merck’s COVID-19 pill
3 years ago

US health panel endorses Merck’s COVID-19 pill

Al Jazeera  

If the FDA authorises the drug, it would be the first at-home treatment for COVID-19 two years into the pandemic. He said FDA would have to carefully tailor the drug’s use for patients who stand to benefit most. If the FDA authorises the drug, it would be the first at-home treatment for the virus nearly two years into the pandemic. …

Merck’s covid-19 pill to be reviewed by FDA advisers
3 years ago

Merck’s covid-19 pill to be reviewed by FDA advisers

Live Mint  

An outside panel of scientific advisers to the Food and Drug Administration is scheduled to meet Tuesday to discuss the experimental Covid-19 oral antiviral from Merck & Co. and partner Ridgeback Biotherapeutics LP. Researchers plan to study molnupiravir and Omicron soon but think the drug could be effective because it has been found to work against other Covid-19 variants, the …

New antiviral drugs are coming for COVID. Here's what you need to know
3 years ago

New antiviral drugs are coming for COVID. Here's what you need to know

NPR  

New antiviral drugs are coming for COVID. Given the higher efficacy of the antibody treatments, "I think we will continue to use those, particularly for high risk people," says Dr. Rajesh Gandhi, an infectious diseases physician at Massachusetts General Hospital and Harvard Medical School who serves on COVID-19 Treatment Guidelines Panels for the NIH and the Infectious Diseases Society of …

Merck’s COVID pill shows lower efficacy in updated study
3 years ago

Merck’s COVID pill shows lower efficacy in updated study

Al Jazeera  

Drugmaker says final analysis of trial results showed molnupiravir led to 30 percent reduction in hospitalisations and deaths, compared with about 50 percent in interim study. Drugmaker Merck’s experimental COVID-19 pill is significantly less effective in slashing hospitalisations and deaths than previously reported, the company has said, following the release of a full analysis of trial results. The United States-based …

Merck asks EU drug regulator to authorise its Covid-19 pill
3 years, 1 month ago

Merck asks EU drug regulator to authorise its Covid-19 pill

Hindustan Times  

The European Medicines Agency said it has received a request from Merck to authorise its coronavirus antiviral, the first pill shown to treat Covid-19. In a statement Tuesday, the EU drug regulator said it had started evaluating molnupiravir, made by Merck and Ridgeback Biotherapeutics, and that a decision could be made within weeks on whether it might be cleared. Last …

EU regulator recommends Merck’s COVID-19 pill for emergency use
3 years, 1 month ago

EU regulator recommends Merck’s COVID-19 pill for emergency use

Al Jazeera  

The European Union’s medicines watchdog has advised its member states they can use a potentially groundbreaking COVID-19 antiviral pill in emergency situations triggered by soaring infection rates, ahead of the treatment’s formal approval across the bloc. Molnupiravir, which is produced by Merck and Ridgeback Biotherapeutics, can be given within five days of first symptoms to treat adults who do not …

Finally, pills to treat Covid-19! All you need to know about Pfizer's Paxlovid and Merck's Molnupiravir
3 years, 1 month ago

Finally, pills to treat Covid-19! All you need to know about Pfizer's Paxlovid and Merck's Molnupiravir

India Today  

Vaccines have been the primary antidote in the battle against Covid-19 to date, but we could have at least two game-changers in the form of American pharmaceutical giant Pfizer's antiviral pill Paxlovid, and Molnupiravir, manufactured by Merck, Sharp and Dohme, and Ridgeback Biotherapeutics. The preliminary data of Pfizer's experimental antiviral pill to treat Covid-19 shows an 89 per cent decrease …

Pfizer says COVID-19 pill cut hospital, death risk by 90%
3 years, 1 month ago

Pfizer says COVID-19 pill cut hospital, death risk by 90%

Associated Press  

WASHINGTON — Pfizer Inc. said Friday that its experimental antiviral pill for COVID-19 cut rates of hospitalization and death by nearly 90% in high-risk adults, as the drugmaker joined the race for an easy-to-use medication to treat the coronavirus. Competitor Merck’s COVID-19 pill is already under review at the Food and Drug Administration after showing strong initial results, and on …

Pfizer says Covid-19 pill is 89% effective in preliminary assessment
3 years, 1 month ago

Pfizer says Covid-19 pill is 89% effective in preliminary assessment

Live Mint  

Pfizer Inc. said a preliminary look at study results indicated that its experimental pill was highly effective at preventing people at high risk of severe Covid-19 from needing hospitalization or dying, the latest encouraging performance for an early virus treatment. The company’s drug cut the risk of hospitalization or death in study subjects with mild to moderate Covid-19 by about …

Pfizer says its COVID-19 pill cuts hospitalisations, death by 89%
3 years, 1 month ago

Pfizer says its COVID-19 pill cuts hospitalisations, death by 89%

Al Jazeera  

Pharmaceutical companies are in a race to manufacture easy-to-use medication against the coronavirus. Pfizer has said its experimental antiviral pill for COVID-19 cuts risk rates of hospitalisation and death by nearly 90 percent, as drugmakers race to manufacture easy-to-use medication against the coronavirus. Of those given Pfizer’s drug within three days of symptom onset 0.8 percent were hospitalised and none …

Britain becomes first country to approve Merck's Covid-19 pill molnupiravir
3 years, 1 month ago

Britain becomes first country to approve Merck's Covid-19 pill molnupiravir

India Today  

Britain on Thursday became the first country in the world to approve a potentially game-changing COVID-19 antiviral pill jointly developed by U.S.-based Merck & Co Inc and Ridgeback Biotherapeutics, in a boost to the fight against the pandemic. Britain's Medicines and Healthcare products Regulatory Agency recommended the drug, molnupiravir, for use in people with mild to moderate COVID-19 and at …

Discover Related